NCT05567185View on ClinicalTrials.gov

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

October 16, 2026

Study Completion Date

September 24, 2027

Conditions
Urinary Bladder NeoplasmsReceptors, Fibroblast Growth Factor
Interventions
DRUG

Erdafitinib Intravesical Delivery System

Erdafitinib intravesical delivery system will be administered.

Trial Locations (4)

216 8511

St Marianna University Hospital, Kanagawa

541 8567

Osaka International Cancer Institute, Osaka

930-0194

Toyama University Hospital, Toyama

305 8576

University of Tsukuba Hospital, Tsukuba

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY